Strozha I, Petukhov V, Bondare D, Feldmane G, Duks A, Teilane I, Medne I, Mauritsas M, Grinberga L
Ter Arkh. 1993;65(10):62-6.
A trial has been conducted of recombinant alpha 2-interferon (reaferon) used in 32 patients with Ph'[correction of Rh']-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.
对32例Ph'[校正为Ph]阳性慢性粒细胞白血病（CML）患者使用重组α2干扰素（利分能）进行了一项试验。其中3例处于慢性期，3例为过渡期，1例为急变期。25例CML患者为新诊断病例。治疗持续2个月至3年。通过常规方法并根据Ph'阳性克隆减少程度确认临床血液学缓解。基于免疫学数据（抗利分能中和抗体检测）试图阐明对利分能耐药的潜在机制。作者提出了一种CML的联合治疗方案（马利兰加利分能），该方案比马利兰单一疗法具有明显优势。
